RXRXRecursion Pharmaceuticals, Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+34% of shares).
Choppy, but holding above its 200-day average. Price is +20% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How RXRX is trading
Recursion Pharmaceuticals, Inc. is −11% over the past year while the S&P 500 is +18%: 30 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +20%
vs 200-day average · a clear uptrend
- RSI (14)
- 56
RSI (14) · neutral
- Below its 52-week high
- 36%
Below its 52-week high
Details›
- Last close2026-10-09
- $4.36
- 1 monthS&P 500 +2.7%
- +38%
- 1 yearS&P 500 +18%
- −11%
- 5 yearsS&P 500 +88%
- −83%
- vs 50-day average$3.55
- +23%
- 52-week high
- $6.79
- 52-week low
- $2.84
- Annualised volatility
- 85%
| Year | Return |
|---|---|
| 2026 (year to date) | +6.5% |
| 2025 | −39% |
| 2024 | −31% |
| 2023 | +28% |
| 2022 | −55% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 3 of 5 | −3.6% |
| Feb | 5 | 2 of 5 | +4.9% |
| Mar | 5 | 0 of 5 | −25% |
| Apr | 5 | 2 of 5 | −9.0% |
| May | 6 | 3 of 6 | +7.7% |
| Jun | 6 | 3 of 6 | +10% |
| Jul | 6 | 4 of 6 | +16% |
| Aug | 6 | 2 of 6 | −8.7% |
| Sep | 6 | 3 of 6 | −0.57% |
| Oct | 6 | 2 of 6 | −5.7% |
| Nov | 5 | 2 of 5 | +2.9% |
| Dec | 5 | 1 of 5 | −0.10% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.